New $1.2 Billion Venture Aims to Breed Superior Military Dogs for U.S. Agencies
Warhound has emerged from stealth with significant funding to develop genetically optimized working dogs equipped with advanced technology.
By Sarah Montgomery ·
A new company called Warhound has officially launched with a $1.2 billion valuation, backed by $200 million in fresh investment. The venture seeks to solve a critical gap in national security by engineering working dogs specifically for the U.S. military, law enforcement, and emergency response teams. This development marks a major shift in how agencies source their canine partners, moving away from traditional breeding methods toward a more technical approach to animal performance.
The startup is supported by prominent investors including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a firm with ties to U.S. intelligence agencies. The core mission of the company is to produce dogs that are genetically suited for demanding missions. According to the launch announcement, over 80% of the U.S. military's working dogs currently come from Europe. Furthermore, fewer than half of these imported animals are deemed fit for service, highlighting a growing reliance on foreign sources for a vital domestic asset.
Warhound aims to fix these supply chain issues by editing the genes of top-performing breeds, such as the Belgian Malinois and German Shepherd. The process involves taking cell lines from these dogs into a biobank to enhance traits like speed, agility, and olfactory sensitivity. The goal is to remove genetic predispositions to common health issues like cancer, hip dysplasia, and muscle atrophy, which often prevent dogs from completing training or serving their full potential.
The project is a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm, who first met Luckey a year ago, explains that the idea stems from a desire to improve the longevity and health of military dogs. Anduril will provide the technological layer, including hardware like protective vests and goggles. These devices will use sensors to give handlers better situational awareness, effectively placing smart technology on top of the dog rather than altering the animal internally.
Colossal Biosciences, known for its work in de-extinction, holds equity in Warhound and licenses its gene-editing technology to the new venture. Viagen, another company owned by Colossal, will handle the cloning process using techniques with high success rates. Lamm stated that the first batch of dogs is currently being cloned and incubated, with births expected early next year. If all goes well, these new animals could begin active service within two years.
The company is working under the guidance of the American Humane Society to certify its training programs. The society views the partnership as an opportunity to ensure ethical treatment of the animals. Warhound plans to sell these enhanced dogs to first responders, the Department of Defense, and police forces, though pricing has not yet been determined. Lamm noted that the company has briefed various government groups and expects the dogs to be trained and managed like any other military working dog.
